ZG005 plus gecacitinib for lymphoma that has returned or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, ZG005 and gecacitinib, for people with lymphoma that has come back or hasn't gotten better with prior treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a type of lymphoma that has returned or not responded to previous treatments.
- You must understand the study and agree to participate by signing a consent form.
- You cannot have lymphoma that has spread to the brain or spinal cord.
- You cannot have serious heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
This trial tests a combination of two new drugs, ZG005 and Gecacitinib, for people with advanced cervical cancer that has spread or come back. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (GCVP) for people with follicular lymphoma who have not had treatment before. The goal is to see if this combination is effective and safe.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.